- Sales in Germany offset by expected slowdown for international distributors after a strong first quarter
- The polyaxial LOQTEC VA foot system will launch in the U.S. market beginning in 2020
- Submitted an application to FDA to conduct human trials of its silver coating technology
- Earnings impacted significantly by one-time effects of early termination of former CEO and associated legal fees
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Trauma | $2.8 | $3.0 | -$0.2 | -7.0% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Trauma | $6.7 | $6.2 | $0.5 | 8.5% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| US | $0.7 | $0.7 | $0.0 | -0.2% |
| Ex-US | $2.1 | $2.3 | -$0.2 | -9.1% |
| Total | $2.8 | $3.0 | -$0.2 | -7.0% |
Source: aap
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Sales in Germany offset by expected slowdown for international distributors after a strong first quarter
The polyaxial LOQTEC VA foot system will launch in the U.S. market beginning in 2020
Submitted an application to FDA to conduct human trials of its silver coating technology
Earnings impacted significantly by one-time...
- Sales in Germany offset by expected slowdown for international distributors after a strong first quarter
- The polyaxial LOQTEC VA foot system will launch in the U.S. market beginning in 2020
- Submitted an application to FDA to conduct human trials of its silver coating technology
- Earnings impacted significantly by one-time effects of early termination of former CEO and associated legal fees
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Trauma | $2.8 | $3.0 | -$0.2 | -7.0% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Trauma | $6.7 | $6.2 | $0.5 | 8.5% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| US | $0.7 | $0.7 | $0.0 | -0.2% |
| Ex-US | $2.1 | $2.3 | -$0.2 | -9.1% |
| Total | $2.8 | $3.0 | -$0.2 | -7.0% |
Source: aap
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.





